Davion Healthcare (DAVI) Registration filing summary

Company overview and business model

• Irish healthcare developer of non-diagnostic home tests for early detection of potential health anomalies; four completed products: BreastCheck, FootFlow, Testic and ThermaDerm.

• Products use liquid-crystal film thermography and AI analysis of smartphone images; results are early-warning indicators and require clinical follow-up for diagnosis.

• Commercial strategy centers on licensing manufacturing, marketing, sales and distribution to regional or global partners; NeuRX holds a global BreastCheck license.

• BreastCheck is expected to launch in the U.S. in H1 2026; FootFlow is anticipated six months later, initially in the U.S., with European and U.K. launches subject to market conditions.

• The NeuRX agreement provides for $120 million in staged license fees and minimum annual royalties of $10 million over an initial 10-year term; fees may be paid in cash or freely tradable NeuRX shares.

Financial performance and metrics

• No revenue through the filing date; operating losses were €277,441 for H1 2025, €1.32 million for FY 2024 and €5.31 million for FY 2023.

• H1 2025 operating loss narrowed from €1.08 million in H1 2024, primarily as executives and directors waived compensation pending Nasdaq listing.

• At June 30, 2025, cash was €4,396, related-party advances were €321,084 and intangible assets were €65 million.

• Management cited CEO financial support and expected NeuRX inflows as sources to meet obligations for at least 12 months; no external financing or investment capital had been raised through the filing date.

• Audited FY 2024 and FY 2023 financial statements were restated; the auditor reported that the statements conform to IFRS and identified material misstatements corrected by the restatement.

Use of proceeds and capital allocation

• No shares are being sold by the issuer and no proceeds will be received from registered shareholder resales; any future capital raise would require a separate registration or exemption.

• Estimated registration and listing expenses total $921,900; cash expenses are funded through non-interest-bearing, unsecured advances from Malbrite Ltd, repayable only upon a future capital raise.

• Available funds and future earnings are intended to be retained for business operations and expansion; no cash dividends are planned for the foreseeable future.